Mitochondrial antiviral signaling protein defect links impaired antiviral response and liver injury in steatohepatitis in mice

Hepatology

Volumn 53, Issue 6, 2011, Pages 1917-1931

  Csak, Timea ^a   Dolganiuc, Angela ^a   Kodys, Karen ^a   Nath, Bharath ^a   Petrasek, Jan ^a   Bala, Shashi ^a   Lippai, Dora ^a   Szabo, Gyongyi ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CARRIER PROTEIN; CASPASE 8; CELL PROTEIN; CYTIDINE; CYTOCHROME C; CYTOKINE; DNA; DOUBLE STRANDED RNA; GUANOSINE; HELICASE; HIGH MOBILITY GROUP B1 PROTEIN; INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 1BETA CONVERTING ENZYME; LIPOPOLYSACCHARIDE; MELANOMA DIFFERENTIATION ASSOCIATED 5; MESSENGER RNA; MITOCHONDRIAL ANTIVIRAL SIGNALING PROTEIN; PHOSPHATE; POLYCYTIDYLIC ACID; POLYINOSINIC ACID; PROTEASOME; PROTEASOME SUBUNIT ALPHA TYPE 7; PROTEIN RIP3; RECEPTOR INTERACTING PROTEIN 3; RETINOIC ACID INDUCIBLE PROTEIN I; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSOL; ENZYME ACTIVATION; FATTY LIVER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNITY; LIVER CELL; LIVER INJURY; MITOCHONDRIAL ANTIVIRAL SIGNALING PROTEIN DEFECT; MITOCHONDRION; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFECT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; BIOPSY; CHOLINE DEFICIENCY; CYTOKINES; DISEASE MODELS, ANIMAL; FATTY LIVER; FEMALE; HUMANS; INTERFERON TYPE I; LIVER; METHIONINE; MICE; MICE, INBRED C57BL; MITOCHONDRIA, LIVER; POLY I-C; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; RNA, DOUBLE-STRANDED;

EID: 79957438570     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24301     Document Type: Article

References (38)

1. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol 2009; 8( Suppl. 1): S4-S8.
2. Selzner M, Rudiger HA, Sindram D, Maddan J, Clavien PA. Mechanisms of ischemic injury are different in the steatotic and normal rat liver. HEPATOLOGY 2000; 32: 1280-1288.
3. Szabo G, Velayudham A, Romics L Jr, Mandrekar P. Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4. Alcohol Clin Exp Res 2005; 29: 140S-145S.
4. Donthamsetty S, Bhave VS, Mitra MS, Latendresse JR, Mehendale HM. Nonalcoholic steatohepatitic (NASH) mice are protected from higher hepatotoxicity of acetaminophen upon induction of PPARalpha with clofibrate. Toxicol Appl Pharmacol 2008; 230: 327-337.
5. Younossi ZM, McCullough AJ. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int 2009; 29( Suppl. 2): 3-12.
6. Kahraman A, Miller M, Gieseler RK, Gerken G, Scolaro MJ, Canbay A. Non-alcoholic fatty liver disease in HIV-positive patients predisposes for acute-on-chronic liver failure: two cases. Eur J Gastroenterol Hepatol 2006; 18: 101-105.
7. Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol 2005; 79: 9369-9380.
8. Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 2005; 122: 669-682.
9. Tang ED, Wang CY. MAVS self-association mediates antiviral innate immune signaling. J Virol 2009; 83: 3420-3428.
10. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845.
11. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006; 6: 1-28.
12. Romics L Jr, Dolganiuc A, Velayudham A, Kodys K, Mandrekar P, Golenbock D, et al. Toll-like receptor 2 mediates inflammatory cytokine induction but not sensitization for liver injury by Propioni-bacterium acnes. J Leukoc Biol 2005; 78: 1255-1264.
13. Jacobs BL, Langland JO. When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. Virology 1996; 219: 339-349.
14. Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann NY Acad Sci 2008; 1143: 1-20.
15. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003; 301: 640-643.
16. Jia Y, Song T, Wei C, Ni C, Zheng Z, Xu Q, et al. Negative regulation of MAVS-mediated immune response by PSMA7. J Immunol 2009; 183: 4241-4248.
17. Baril M, Racine ME, Penin F, Lamarre D. MAVS dimer is crucial signaling component of innate immunity and the target of hepatitis C virus NS3/4A protease. J Virol 2009; 83: 1299-1311.
18. Wei Y, Rector RS, Thyfault JP, Ibdah JA. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 2008; 14: 193-199.
19. Caroppi P, Sinibaldi F, Fiorucci L, Santucci R. Apoptosis and human diseases: mitochondrion damage and lethal role of released cytochrome C as proapoptotic protein. Curr Med Chem 2009; 16: 4058-4065.
20. Rebsamen M, Meylan E, Curran J, Tschopp J. The antiviral adaptor proteins Cardif and Trif are processed and inactivated by caspases. Cell Death Differ 2008; 15: 1804-1811.
21. Scott I, Norris KL. The mitochondrial antiviral signaling protein, MAVS, is cleaved during apoptosis. Biochem Biophys Res Commun 2008; 375: 101-106.
22. Yu CY, Chiang RL, Chang TH, Liao CL, Lin YL. The interferon stimulator mitochondrial antiviral signaling protein facilitates cell death by disrupting mitochondrial membrane potential and by activating caspases. J Virol 2010; 84: 2421-2431.
23. Dong Z, Wei H, Sun R, Hu Z, Gao B, Tian Z. Involvement of natural killer cells in polyI:C-induced liver injury. J Hepatol 2004; 41: 966-973.
24. Kahraman A, Schlattjan M, Kocabayoglu P, Yildiz-Meziletoglu S, Schlensak M, Fingas CD, et al. Major histocompatibility complex class I-related chains A and B (MIC A/B): A novel role in nonalcoholic steatohepatitis. HEPATOLOGY 2010; 51: 92-102.
25. Lei Y, Moore CB, Liesman RM, O'Connor BP, Bergstralh DT, Chen ZT, et al. MAVS-mediated apoptosis and its inhibition by viral proteins. PLoS One 2009; 4: e5466.
26. Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009; 325: 332-336.
27. Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, Matsui K, et al. Cell-type specific involvement of RIG-I in antiviral response. Immunity 2005; 23: 19-28.
28. McCartney S, Vermi W, Gilfillan S, Cella M, Murphy TL, Schreiber RD, et al. Distinct and complementary functions of Mda5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J Exp Med 2009; 206: 2967-2976.
29. Duluc D, Tan F, Scotet M, Blanchard S, Fremaux I, Garo E, et al. Poly I:C plus IL-2 or IL-12 induce IFNγ production by human NK cells via autocrine IFN-β. Eur J Immunol 2009; 39: 2877-2884.
30. Ohman T, Rintahaka J, Kalkkinen N, Matikainen S, Nyman TA. Actin and RIG-I/MAVS signaling components translocate to mitochondria upon influenza A virus infection of human primary macrophages. J Immunol 2009; 182: 5682-5692.
31. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. HEPATOLOGY 2006; 44: 27-33.
32. Farrell GC, Larter CZ, Hou JY, Zhang RH, Yeh MM, Williams J, et al. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. J Gastroenterol Hepatol 2009; 24: 443-452.
33. Peters JM, Franke WW, Kleinschmidt JA. Distinct 19S and 20S subcomplexes of the 26S proteasome and their distribution in the nucleusand cytoplasm. J Biol Chem 1994; 269: 7709-7718.
34. Besch R, Poeck H, Hohenauer T, Senft D, Hacker G, Berking C, et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type-I interferon-independent apoptosis in human melanoma cells. J Clin Invest 2009; 119: 2399-2411.
35. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, et al. IPS-1, an adaptor triggering RIG-I and Mda5-mediated type I interferon induction. Nat Immunol 2005; 6: 981-988.
36. Vandenbeele P, Declerq W, Van Herreweghe F, Vanden Berghe T. The role of the kinases RIP1 and RIP3 in TNF-induced necrosis. Sci Signal 2010; 3: re4.
37. He S, Wang L, Miao L, Wang T, Du F, Zhao L, et al. Receptor-interacting protein kinase 3 determines cellular necrotic response to TNF-alpha. Cell 2009; 137: 1100-1111.
38. Davis CW, Hawkins BJ, Ramasamy S, Irrinki KM, Cameron BA, Islam K, et al. Nitration of the mitochondrial complex I subunit NDUFB8 elicits RIP1- and RIP3-mediated necrosis. Free Radic Biol Med 2010; 48: 306-317.